▲ +82.76% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Pulse Biosciences in the last 3 months. The average price target is $46.00, with a high forecast of $46.00 and a low forecast of $46.00. The average price target represents a 82.76% upside from the last price of $25.17.
The current consensus among 1 contributing investment analysts is to buy stock in Pulse Biosciences. This Buy consensus rating has held steady for over two years.
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It engages in the research and development, and commercialization of CellFX system that provides a precise and non-thermal cellular treatment technology delivering nanosecond duration energy pulses that impact cells in treated tissue while sparing surrounding non-cellular tissue primarily for dermatology applications. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was founded in 2014 and is headquartered in Hayward, California.